Literature DB >> 28535519

Development of the New Kibou® Equipment for Continuous Renal Replacement Therapy from Scratch to the Final Configuration.

Mauro Neri, Anna Lorenzin, Alessandra Brendolan, Francesco Garzotto, Fiorenza Ferrari, Silvia De Rosa, Raffaele Bonato, Gianluca Villa, Simona Bazzano, Fiorella D''Ippoliti, Zaccaria Ricci, Gaetano La Manna, Claudio Ronco.   

Abstract

A new technology has recently appeared in the area of extracorporeal therapies for critically ill patients with acute kidney injury. The International Renal Research Institute of Vicenza was involved from the beginning in the development of a new continuous renal replacement therapy (CRRT) equipment with peculiar characteristics. We report the overall experience from design of the new machine to its in vitro and in vivo testing. Kibou® (Asahi Kasei Kuraray Medical Co., Ltd., Tokyo, Japan) is a new multifunctional machine designed for delivering RRT. Kibou® carries out many features of the fourth generation CRRT machines including the possibility of a dynamic prescription and reduction of nursing workload. We describe our first experience with this new device, focusing on several usability and performance parameters. A specific in vitro protocol was designed to analyze the various characteristics and accuracy of performance of the machine. Furthermore, a preliminary in vivo alpha trial with 12 CRRT sessions was performed to test, characterize and evaluate the machine in terms of usability, flexibility and reliability. The in vitro evaluation confirmed an adequate design and a good usability of the machine with accurate delivery of prescribed parameters. No adverse events were observed during the in vivo test that confirmed usability and safety together with accuracy of treatment delivery in different modalities. In general, the machine was rated by physicians and nurses involved in the evaluation as practical and easy to use, although a specific training is required to familiarize with the equipment. A large-scale multicenter beta trial is required to confirm the results reported in this preliminary evaluation in terms of safety, accuracy and performance of Kibou®.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28535519     DOI: 10.1159/000468914

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  2 in total

1.  ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study).

Authors:  Mauro Neri; Anna Lorenzin; Massimo de Cal; Alessandra Brendolan; Nicola Marchionna; Sara Samoni; Monica Zanella; Silvia De Rosa; Francesca Martino; Zaccaria Ricci; Javier Maynar; Georg Auzinger; Gianluca Villa; Didier Payen; Michael Joannidis; Claudio Ronco
Journal:  Blood Purif       Date:  2019-02-01       Impact factor: 2.614

Review 2.  Methods for dose quantification in continuous renal replacement therapy: Toward a more precise approach.

Authors:  Gianluca Villa; Sergio Fabbri; Sara Samoni; Matteo Cecchi; Antonio Fioccola; Caterina Scirè-Calabrisotto; Gaia Mari; Diego Pomarè Montin; Stefano Romagnoli
Journal:  Artif Organs       Date:  2021-08-18       Impact factor: 3.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.